Actual Medicinal Product (AMP) Urispas 200 tablets (Lexon (UK) Ltd)

This product can't be added to an MCA list.

Stability Information

(Some stability information inherited from generic)

Stability
compatible_special_measures logo Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

Protect from light.

Provenance

This compatibility recommendation is derived from Urispas 200 tablets (Recordati Pharmaceuticals Ltd).

Generic
Flavoxate
Formulation
Flavoxate 200mg tablets
  • Flavoxate
    • Flavoxate 200mg tablets

      • Urispas 200 tablets (Lexon (UK) Ltd)



Related Formulations (1)

compatible_special_measures logo Flavoxate 200mg tablets